NCT06247241View on ClinicalTrials.gov

A Phase 2a Study To Evaluate VMB-100 In Females With Stress Urinary Incontinence

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

April 30, 2029

Conditions

Stress Urinary Incontinence

Interventions

DRUG

VMB-100

VMB-100 is administered as intrasphincteric injection in the urethra sphincter

Sponsors

Collaborators (1)

PPD Development, LP

All Listed Sponsors

collaborator

PPD Development, LP

INDUSTRY

lead

Versameb AG

INDUSTRY